Payment overview · 2025
General Payments
$187.95
9 reported records · 7 companies
Healthcare provider profile · identity verified
Govind Singh, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLFAX, WA · NPI 1730199464
Verified facts
What the public records show
CMS Open Payments records show Govind Singh, M.D. received $187.95 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.44 | 33.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.31 | 14.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.62 | 12.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.42 | 11.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.02 | 10.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.30 | 9.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.84 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $187.95 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.44 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 102 |
| Losartan Potassium | Losartan Potassium | 378 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 66 |
| Omeprazole | Omeprazole | 262 | 58 |
| Carvedilol | Carvedilol | 257 | 42 |
| Lisinopril | Lisinopril | 252 | 63 |
| Potassium Chloride | Potassium Chloride | 225 | 42 |
| Eliquis | Apixaban | 210 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 39 |
| Gabapentin | Gabapentin | 180 | 32 |
| Allopurinol | Allopurinol | 177 | 31 |
| Spironolactone | Spironolactone | 170 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 37 |
| Trazodone Hcl | Trazodone Hcl | 163 | 37 |
| Famotidine | Famotidine | 156 | 28 |
| Furosemide | Furosemide | 153 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 26 |
| Jardiance | Empagliflozin | 134 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 25 |
| Metformin Hcl | Metformin Hcl | 126 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 26 |
| Metformin Hcl Er | Metformin Hcl | 117 | 33 |
| Ezetimibe | Ezetimibe | 110 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 18 |
| Memantine Hcl | Memantine Hcl | 99 | 16 |
| Pregabalin | Pregabalin | 99 | 25 |
| Xarelto | Rivaroxaban | 99 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 20 |
| Meloxicam | Meloxicam | 93 | 19 |
| Ozempic | Semaglutide | 93 | 20 |
| Celecoxib | Celecoxib | 90 | 21 |
| Sertraline Hcl | Sertraline Hcl | 90 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 18 |
| Donepezil Hcl | Donepezil Hcl | 84 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 23 |
| Simvastatin | Simvastatin | 82 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 13 |
| Farxiga | Dapagliflozin Propanediol | 73 | 13 |
| Alendronate Sodium | Alendronate Sodium | 69 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 12 |
| Lorazepam | Lorazepam | 66 | 17 |
| Bupropion Xl | Bupropion Hcl | 65 | 15 |
| Finasteride | Finasteride | 65 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 22 |
| Nortriptyline Hcl | Nortriptyline Hcl | 58 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 50 | 12 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Ramipril | Ramipril | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 12 |
| Prednisone | Prednisone | 38 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Digoxin | Digoxin | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Travatan Z | Travoprost | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Budesonide Ec | Budesonide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $187.95 · 9 records | Amgen Inc. | CAPLYTA, EVENITY, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error